Latest / Applied Clinical Trials
ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials
In today’s ACT Brief, we spotlight the industry’s push to reduce site technology burden, AstraZeneca’s broad survival gains from the MATTERHORN trial, and Thermo Fisher’s multibillion-dollar acquisition of Clario to advance AI-driven clinical research.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.